Literature DB >> 26541578

Design of a fluorescent ligand targeting the S-adenosylmethionine binding site of the histone methyltransferase MLL1.

Yepeng Luan1, Levi L Blazer, Hao Hu, Taraneh Hajian, Jing Zhang, Hong Wu, Scott Houliston, Cheryl H Arrowsmith, Masoud Vedadi, Yujun George Zheng.   

Abstract

The histone methyltransferase MLL1 has been linked to translocation-associated gene fusion in childhood leukemias and is an attractive drug target. High-throughput biochemical analysis of MLL1 methyltransferase activity requires the production of at least a trimeric complex of MLL1, RbBP5 and WDR5 to elicit robust activity. Production of trimeric and higher order MLL1 complexes in the quantities and reproducibility required for high-throughput screening presents a significant impediment to MLL1 drug discovery efforts. We present here a small molecule fluorescent ligand (FL-NAH, 6) that is able to bind to the S-adenosylmethionine (SAM) binding site of MLL1 in a manner independent of the associated complex members. We have used FL-NAH to develop a fluorescence polarization-based SAM displacement assay in a 384-well format targeting the MLL1 SET domain in the absence of associated complex members. FL-NAH competes with SAM and is displaced from the MLL1 SET domain by other SAM-binding site ligands with Kdisp values similar to the higher-order complexes, but is unaffected by the H3 peptide substrate. This assay enables screening for SAM-competitive MLL1 inhibitors without requiring the use of trimeric or higher order MLL1 complexes, significantly reducing screening time and cost.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26541578      PMCID: PMC4689628          DOI: 10.1039/c5ob01794g

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  26 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Authors:  Jolanta Grembecka; Shihan He; Aibin Shi; Trupta Purohit; Andrew G Muntean; Roderick J Sorenson; Hollis D Showalter; Marcelo J Murai; Amalia M Belcher; Thomas Hartley; Jay L Hess; Tomasz Cierpicki
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

Review 3.  Challenges and opportunities in targeting the menin-MLL interaction.

Authors:  Tomasz Cierpicki; Jolanta Grembecka
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

4.  CpG-binding protein (CXXC finger protein 1) is a component of the mammalian Set1 histone H3-Lys4 methyltransferase complex, the analogue of the yeast Set1/COMPASS complex.

Authors:  Jeong-Heon Lee; David G Skalnik
Journal:  J Biol Chem       Date:  2005-10-26       Impact factor: 5.157

Review 5.  Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.

Authors:  Chun-Wei Chen; Scott A Armstrong
Journal:  Exp Hematol       Date:  2015-06-25       Impact factor: 3.084

6.  Design, synthesis, and kinetic analysis of potent protein N-terminal methyltransferase 1 inhibitors.

Authors:  Gang Zhang; Stacie Lynn Richardson; Yunfei Mao; Rong Huang
Journal:  Org Biomol Chem       Date:  2015-02-25       Impact factor: 3.876

7.  Using S-adenosyl-L-homocysteine capture compounds to characterize S-adenosyl-L-methionine and S-adenosyl-L-homocysteine binding proteins.

Authors:  Lindsey J Brown; Matthias Baranowski; Yun Wang; Anna K Schrey; Thomas Lenz; Sean D Taverna; Philip A Cole; Michael Sefkow
Journal:  Anal Biochem       Date:  2014-08-27       Impact factor: 3.365

8.  Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes.

Authors:  Rick van Nuland; Arne H Smits; Paschalina Pallaki; Pascal W T C Jansen; Michiel Vermeulen; H T Marc Timmers
Journal:  Mol Cell Biol       Date:  2013-03-18       Impact factor: 4.272

9.  Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5.

Authors:  Guillermo Senisterra; Hong Wu; Abdellah Allali-Hassani; Gregory A Wasney; Dalia Barsyte-Lovejoy; Ludmila Dombrovski; Aiping Dong; Kong T Nguyen; David Smil; Yuri Bolshan; Taraneh Hajian; Hao He; Alma Seitova; Irene Chau; Fengling Li; Gennadiy Poda; Jean-François Couture; Peter J Brown; Rima Al-Awar; Matthieu Schapira; Cheryl H Arrowsmith; Masoud Vedadi
Journal:  Biochem J       Date:  2013-01-01       Impact factor: 3.857

10.  High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction.

Authors:  Shihan He; Timothy J Senter; Jonathan Pollock; Changho Han; Sunil Kumar Upadhyay; Trupta Purohit; Rocco D Gogliotti; Craig W Lindsley; Tomasz Cierpicki; Shaun R Stauffer; Jolanta Grembecka
Journal:  J Med Chem       Date:  2014-02-06       Impact factor: 7.446

View more
  4 in total

1.  Chemical Proteomic Profiling of Human Methyltransferases.

Authors:  Benjamin D Horning; Radu M Suciu; Darian A Ghadiri; Olesya A Ulanovskaya; Megan L Matthews; Kenneth M Lum; Keriann M Backus; Steven J Brown; Hugh Rosen; Benjamin F Cravatt
Journal:  J Am Chem Soc       Date:  2016-09-30       Impact factor: 15.419

2.  Hyperhomocysteinemia in ApoE-/- Mice Leads to Overexpression of Enhancer of Zeste Homolog 2 via miR-92a Regulation.

Authors:  Yang Xiaoling; Zhao Li; Li ShuQiang; Ma Shengchao; Yang Anning; Ding Ning; Li Nan; Jia Yuexia; Yang Xiaoming; Li Guizhong; Jiang Yideng
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

Review 3.  Targeting human SET1/MLL family of proteins.

Authors:  Masoud Vedadi; Levi Blazer; Mohammad S Eram; Dalia Barsyte-Lovejoy; Cheryl H Arrowsmith; Taraneh Hajian
Journal:  Protein Sci       Date:  2017-03-06       Impact factor: 6.725

4.  Synthesis and Activity of Triazole-Adenosine Analogs as Protein Arginine Methyltransferase 5 Inhibitors.

Authors:  Tyler Brown; Mengtong Cao; Y George Zheng
Journal:  Molecules       Date:  2022-06-11       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.